Is lipoprotein(a) an independent risk factor for ischemic heart disease in men? The Quebec Cardiovascular Study
B Cantin,
F Gagnon,
S Moorjani,
JP Despres,
B Lamarche,
PJ Lupien,
and
GR Dagenais
Lipid Research Centre, Laval University Medical Centre and Faculty of Medicine, Laval University, Ste-Foy, Quebec, Canada. CLajoie@sympatico.ca
OBJECTIVES: This study was undertaken to determine whether lipoprotein(a) [Lp(a)] is an independent risk factor for ischemic heart disease (IHD) and to establish the relation of Lp(a) to the other lipid fractions. BACKGROUND: Several, but not all, studies have shown that elevated Lp(a) concentrations may be associated with IHD; very few have been prospective. METHODS: A 5-year prospective follow-up study was conducted in 2,156 French Canadian men 47 to 76 years old, without clinical evidence of IHD. Lipid measurements obtained at baseline included total cholesterol, low density lipoprotein (LDL) cholesterol, high density lipoprotein (HDL) cholesterol, apoprotein B and Lp(a). During the follow-up period, there were 116 first IHD events (myocardial infarction, angina, death). Adjusted proportional hazards models were used to estimate the relative risk for the different variables. The cohort was also classified according to Lp(a) levels and other lipid risk factor tertiles to evaluate the relation of elevated Lp(a) levels to these risk factors. A cutoff value of 30 mg/dl was used for Lp(a). Risk ratios were calculated using the group with low Lp(a) levels and the first tertile of lipid measures as a reference. RESULTS: Lp(a) was not an independent risk factor for IHD but seemed to increase the deleterious effects of mildly elevated LDL cholesterol and elevated total cholesterol and apoprotein B levels and seemed to counteract the beneficial effects associated with elevated HDL cholesterol levels. CONCLUSIONS: In this cohort, Lp(a) was not an independent risk factor for IHD but appeared to increase the risk associated with other lipid risk factors.
This article has been cited by other articles:

|
 |

|
 |
 
B. G. Nordestgaard, M. J. Chapman, K. Ray, J. Boren, F. Andreotti, G. F. Watts, H. Ginsberg, P. Amarenco, A. Catapano, O. S. Descamps, et al.
Lipoprotein(a) as a cardiovascular risk factor: current status
Eur. Heart J.,
December 1, 2010;
31(23):
2844 - 2853.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. J. Nicholls, W. H. W. Tang, H. Scoffone, D. M. Brennan, J. Hartiala, H. Allayee, and S. L. Hazen
Lipoprotein(a) levels and long-term cardiovascular risk in the contemporary era of statin therapy
J. Lipid Res.,
October 1, 2010;
51(10):
3055 - 3061.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Helfand, D. I. Buckley, M. Freeman, R. Fu, K. Rogers, C. Fleming, and L. L. Humphrey
Emerging Risk Factors for Coronary Heart Disease: A Summary of Systematic Reviews Conducted for the U.S. Preventive Services Task Force
Ann Intern Med,
October 6, 2009;
151(7):
496 - 507.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
The Emerging Risk Factors Collaboration
Lipoprotein(a) Concentration and the Risk of Coronary Heart Disease, Stroke, and Nonvascular Mortality
JAMA,
July 22, 2009;
302(4):
412 - 423.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. H. DESSEIN, B. F. CHRISTIAN, and A. SOLOMON
Which Are the Determinants of Dyslipidemia in Rheumatoid Arthritis and Does Socioeconomic Status Matter in This Context?
J Rheumatol,
July 1, 2009;
36(7):
1357 - 1361.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. H. Samson
The Role of Statin Drugs in the Management of the Peripheral Vascular Patient
Vascular and Endovascular Surgery,
August 1, 2008;
42(4):
352 - 366.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Bennet, E. Di Angelantonio, S. Erqou, G. Eiriksdottir, G. Sigurdsson, M. Woodward, A. Rumley, G. D. O. Lowe, J. Danesh, and V. Gudnason
Lipoprotein(a) Levels and Risk of Future Coronary Heart Disease: Large-Scale Prospective Data
Arch Intern Med,
March 24, 2008;
168(6):
598 - 608.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. R. Kamstrup, M. Benn, A. Tybjaerg-Hansen, and B. G. Nordestgaard
Extreme Lipoprotein(a) Levels and Risk of Myocardial Infarction in the General Population: The Copenhagen City Heart Study
Circulation,
January 15, 2008;
117(2):
176 - 184.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Assmann
Dyslipidaemia and global cardiovascular risk: clinical issues
Eur. Heart J. Suppl.,
October 1, 2006;
8(suppl_F):
F40 - F46.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Suk Danik, N. Rifai, J. E. Buring, and P. M Ridker
Lipoprotein(a), measured with an assay independent of apolipoprotein(a) isoform size, and risk of future cardiovascular events among initially healthy women.
JAMA,
September 20, 2006;
296(11):
1363 - 1370.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Berglund and R. Ramakrishnan
Lipoprotein(a): An Elusive Cardiovascular Risk Factor
Arterioscler Thromb Vasc Biol,
December 1, 2004;
24(12):
2219 - 2226.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. M. Marcovina, M. L. Koschinsky, J. J. Albers, and S. Skarlatos
Report of the National Heart, Lung, and Blood Institute Workshop on Lipoprotein(a) and Cardiovascular Disease: Recent Advances and Future Directions
Clin. Chem.,
November 1, 2003;
49(11):
1785 - 1796.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Imhof, D. Rothenbacher, N. Khuseyinova, A. Hoffmeister, W. Maerz, M. Nauck, H. Scharnagl, W. Koenig, and H. Brenner
Plasma lipoprotein Lp(a), markers of haemostasis and inflammation, and risk and severity of coronary heart disease
European Journal of Cardiovascular Prevention & Rehabilitation,
October 1, 2003;
10(5):
362 - 370.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Sun, H. Unoki, X. Wang, J. Liang, T. Ichikawa, Y. Arai, M. Shiomi, S. M. Marcovina, T. Watanabe, and J. Fan
Lipoprotein(a) Enhances Advanced Atherosclerosis and Vascular Calcification in WHHL Transgenic Rabbits Expressing Human Apolipoprotein(a)
J. Biol. Chem.,
November 27, 2002;
277(49):
47486 - 47492.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. A. Fung and J. J. Frohlich
Common problems in the management of hypertriglyceridemia
Can. Med. Assoc. J.,
November 26, 2002;
167(11):
1261 - 1266.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Peltier, M. C. Iannetta Peltier, M. E. Sarano, J.-P. M. Lesbre, J.-L. Colas, and C. M. Tribouilloy
Elevated Serum Lipoprotein(a) Level Is an Independent Marker of Severity of Thoracic Aortic Atherosclerosis*
Chest,
May 1, 2002;
121(5):
1589 - 1594.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
I. Lemieux, B. Lamarche, C. Couillard, A. Pascot, B. Cantin, J. Bergeron, G. R. Dagenais, and J.-P. Despres
Total Cholesterol/HDL Cholesterol Ratio vs LDL Cholesterol/HDL Cholesterol Ratio as Indices of Ischemic Heart Disease Risk in Men: The Quebec Cardiovascular Study
Arch Intern Med,
December 10, 2001;
161(22):
2685 - 2692.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Ricci, G. Tamaro, R. Simeone, E. Giolo, G. Nucera, F. De Seta, and S. Guaschino
Lipoprotein(a) changes during natural menstrual cycle and ovarian stimulation with recombinant and highly purified urinary FSH
Hum. Reprod.,
March 1, 2001;
16(3):
449 - 456.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. von Eckardstein, H. Schulte, P. Cullen, and G. Assmann
Lipoprotein(a) further increases the risk of coronary events in men with high global cardiovascular risk
J. Am. Coll. Cardiol.,
February 1, 2001;
37(2):
434 - 439.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Danesh, R. Collins, and R. Peto
Lipoprotein(a) and Coronary Heart Disease : Meta-Analysis of Prospective Studies
Circulation,
September 5, 2000;
102(10):
1082 - 1085.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. M. Marcovina and M. L. Koschinsky
Lipoprotein(a) Concentration and Apolipoprotein(a) Size : A Synergistic Role in Advanced Atherosclerosis?
Circulation,
September 14, 1999;
100(11):
1151 - 1153.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. J. Harjai
Potential New Cardiovascular Risk Factors: Left Ventricular Hypertrophy, Homocysteine, Lipoprotein(a), Triglycerides, Oxidative Stress, and Fibrinogen
Ann Intern Med,
September 7, 1999;
131(5):
376 - 386.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. J. Seman, C. DeLuca, J. L. Jenner, L. A. Cupples, J. R. McNamara, P. W.F. Wilson, W. P. Castelli, J. M. Ordovas, and E. J. Schaefer
Lipoprotein(a)-Cholesterol and Coronary Heart Disease in the Framingham Heart Study
Clin. Chem.,
July 1, 1999;
45(7):
1039 - 1046.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
O. T. Raitakari, M. R. Adams, and D. S. Celermajer
Effect of Lp(a) on the Early Functional and Structural Changes of Atherosclerosis
Arterioscler Thromb Vasc Biol,
April 1, 1999;
19(4):
990 - 995.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Wehinger, A. Kastrati, S. Elezi, H. Baum, S. Braun, F.-J. Neumann, and A. Schomig
Lipoprotein(a) and coronary thrombosis and restenosis after stent placement
J. Am. Coll. Cardiol.,
March 15, 1999;
33(4):
1005 - 1012.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Gazzaruso, A. Garzaniti, P. Buscaglia, G. Bonetti, C. Falcone, P. Fratino, G. Finardi, and D. Geroldi
Association between apolipoprotein(a) phenotypes and coronary heart disease at a young age
J. Am. Coll. Cardiol.,
January 1, 1999;
33(1):
157 - 163.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|